PGM is pleased to announce the enrollment of the twentieth patient in its IDE-approved clinical safety study for its RegennTM Negative Pressure Therapy System (NPTS).  “We are pleased with our clinical experience of the RegennTM NPTS and continue to work with the PGM team to bring this study to a successful completion”, Joshua Bunch, MD, Principle Investigator.  CEO, Neal Vail, said, “Patient enrollment is on track, putting us in a strong position to complete this study in the first half of 2026”.  San Antonio, TX, USA. December 2025.